{"resourceType":"PlanDefinition","id":"chlamydia-screening-intervention","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/chlamydia-screening-intervention\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003eChlamydiaScreening_CDS_UsingCommon\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eChalmydia Screening CDS Example Using Common\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003edraft\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eChlamydia Screening CDS Example Using Common\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eChlamydia Screening\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/example\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003ePatient has not had chlamydia screening within the recommended timeframe...\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                  \u003c/span\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eNoScreening\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"identifier":[{"use":"official","value":"ChlamydiaScreening_CDS_UsingCommon"}],"version":"2.0.0","title":"Chalmydia Screening CDS Example Using Common","status":"draft","date":"2015-07-22","description":"Chlamydia Screening CDS Example Using Common","topic":[{"text":"Chlamydia Screening"}],"library":["http://example.org/fhir/Library/example"],"action":[{"title":"Patient has not had chlamydia screening within the recommended timeframe...","condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"NoScreening"}}],"dynamicValue":[{"path":"$this","expression":{"language":"text/cql","expression":"ChlamydiaScreeningRequest"}}]}]}
{"resourceType":"PlanDefinition","id":"example-cardiology-os","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example-cardiology-os\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://va.gov/kas/orderset/B5-Cardiology-ChestPainCAD-OS\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: bb7ccea6-9744-4743-854a-bcffd87191f6 (OFFICIAL), id: CLIN0004AG, id: KP-914\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: ChestPainCoronaryArteryDiseaseOrderSetKNART\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Chest Pain (CP) - Coronary Artery Disease (CAD) Order Set KNART\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eOrder Set\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: active\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2017-08-29\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Department of Veterans Affairs\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: The Cardiology chest pain (CP) and coronary artery disease (CAD) group of KNARTs are     intended to assist primary care providers in the management of adult patients with stable     chest pain (with or without known CAD); aid in determining when a cardiology consultation is     appropriate; provide guidance for initial noninvasive diagnostic orders (stress testing) and     provide a structured documentation template for the process. Stable patients with cardiac     chest pain require risk stratification, office-based workup, initiation of disease-specific     medications, and subspecialty referral to a cardiologist.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: The Cardiology chest pain (CP) and coronary artery disease (CAD) group of KNARTs are intended to assist primary care providers in the management of adult patients with stable chest pain (with or without known CAD); aid in determining when a cardiology consultation is appropriate; provide guidance for initial noninvasive diagnostic orders (stress testing) and provide a structured documentation template for the process. Stable patients with cardiac chest pain require risk stratification, office-based workup, initiation of disease-specific medications, and subspecialty referral to a cardiologist. This context excludes emergent patients (new/ongoing/unstable pattern CP). Included are those patients with stable CP with or without known CAD, to be considered for evaluation by cardiology.\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © Copyright Cognitive Medical Systems, Inc. 9444 Waples Street Suite 300 San Diego, CA 92121\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Bruce Bray MD: , Scott Wall MD: , Aiden Abidov MD, PhD: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: , , , , , , , , , , , \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003e#cardiology-chestPain-logic\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"contained":[{"resourceType":"Library","id":"cardiology-chestPain-logic","status":"active","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/library-type","code":"logic-library","display":"Logic Library"}]},"description":"Placeholder library"},{"resourceType":"ActivityDefinition","id":"referralToCardiologyConsult","status":"draft","description":"Consider other consult modalities which might be available (e.g., e-consult or other rapidly iterative consult method. A simple consult is included here as the overarching clinical intent.","kind":"ServiceRequest","timingTiming":{"_event":[{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-expression","valueExpression":{"language":"text/cql","expression":"Now()"}}]}]},"participant":[{"type":"practitioner"}]},{"resourceType":"ActivityDefinition","id":"metoprololTartrate25Prescription","status":"draft","kind":"MedicationRequest","productReference":{"reference":"#metoprololTartrate25Medication"},"dosage":[{"text":"1 tablet oral 2 time daily","timing":{"repeat":{"frequency":2,"period":1,"periodUnit":"d"}},"route":{"coding":[{"code":"26643006","display":"Oral route (qualifier value)"}],"text":"Oral route (qualifier value)"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"value":1,"unit":"{tbl}"}}]}],"dynamicValue":[{"path":"medicationRequest.priority","expression":{"language":"text/cql","expression":"routine"}}]},{"resourceType":"Medication","id":"metoprololTartrate25Medication","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"866426"}],"text":"Metoprolol Tartrate 25 MG"},"doseForm":{"coding":[{"system":"http://snomed.info/sct","code":"385055001","display":"Tablet dose form"}],"text":"Tablet dose form"},"ingredient":[{"item":{"reference":{"reference":"#metoprololTartrate25Substance"}},"strengthRatio":{"numerator":{"value":25,"unit":"mg"},"denominator":{"value":1,"unit":"{tbl}"}}}]},{"resourceType":"Substance","id":"metoprololTartrate25Substance","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6918"}],"text":"Metoprolol"}},{"resourceType":"ActivityDefinition","id":"metoprololTartrate50Prescription","status":"draft","kind":"MedicationRequest","productReference":{"reference":"#metoprololTartrate50Medication"},"dosage":[{"text":"1 tablet oral 2 time daily","timing":{"repeat":{"frequency":2,"period":1,"periodUnit":"d"}},"route":{"coding":[{"code":"26643006","display":"Oral route (qualifier value)"}],"text":"Oral route (qualifier value)"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"value":1,"unit":"{tbl}"}}]}],"dynamicValue":[{"path":"medicationRequest.priority","expression":{"language":"text/cql","expression":"routine"}}]},{"resourceType":"Medication","id":"metoprololTartrate50Medication","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"866435"}],"text":"Metoprolol Tartrate 50 MG"},"doseForm":{"coding":[{"system":"http://snomed.info/sct","code":"385055001","display":"Tablet dose form"}],"text":"Tablet dose form"},"ingredient":[{"item":{"reference":{"reference":"#metoprololTartrate50Substance"}},"strengthRatio":{"numerator":{"value":50,"unit":"mg"},"denominator":{"value":1,"unit":"{tbl}"}}}]},{"resourceType":"Substance","id":"metoprololTartrate50Substance","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6918"}],"text":"Metoprolol"}},{"resourceType":"ActivityDefinition","id":"nitroglycerinPrescription","status":"draft","kind":"MedicationRequest","productReference":{"reference":"#nitroglycerinMedication"},"dosage":[{"text":"nitroglycerin 0.4 mg tablet sub-lingual every 5 minutes as needed for chest pain; maximum 3 tablets","timing":{"repeat":{"frequency":1,"period":5,"periodUnit":"min"}},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"value":1,"unit":"{tbl}"}}],"maxDosePerAdministration":{"value":3,"unit":"{tbl}"}}],"dynamicValue":[{"path":"medicationRequest.priority","expression":{"language":"text/cql","expression":"routine"}}]},{"resourceType":"Medication","id":"nitroglycerinMedication","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"316365"}],"text":"Nitroglycerin 0.4 MG"},"doseForm":{"coding":[{"system":"http://snomed.info/sct","code":"385055001","display":"Tablet dose form"}],"text":"Tablet dose form"},"ingredient":[{"item":{"reference":{"reference":"#nitroglycerinSubstance"}},"strengthRatio":{"numerator":{"value":0.4,"unit":"mg"},"denominator":{"value":1,"unit":"{tbl}"}}}]},{"resourceType":"Substance","id":"nitroglycerinSubstance","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"4917"}],"text":"Nitroglycerin"}},{"resourceType":"Questionnaire","id":"CollectReferralReason","status":"draft","item":[{"linkId":"1","text":"Reason for Cardiology Consult","type":"choice","required":true,"repeats":true,"answerValueSet":"#CardiologyReferralReasonValues"}]},{"resourceType":"Questionnaire","id":"CardiologyConsultationGoal","status":"draft","item":[{"linkId":"2","text":"Goal of cardiology consultation","type":"string"}]}],"url":"http://va.gov/kas/orderset/B5-Cardiology-ChestPainCAD-OS","identifier":[{"use":"official","system":"urn:va.gov:kbs:knart:artifact:r1","value":"bb7ccea6-9744-4743-854a-bcffd87191f6"},{"system":"urn:va.gov:kbs:contract:VA118-16-D-1008:to:VA-118-16-F-1008-0007","value":"CLIN0004AG"},{"system":"urn:cognitivemedicine.com:lab:jira","value":"KP-914"}],"version":"0.1","name":"ChestPainCoronaryArteryDiseaseOrderSetKNART","title":"Chest Pain (CP) - Coronary Artery Disease (CAD) Order Set KNART","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"order-set","display":"Order Set"}]},"status":"active","date":"2017-08-29","publisher":"Department of Veterans Affairs","description":"The Cardiology chest pain (CP) and coronary artery disease (CAD) group of KNARTs are     intended to assist primary care providers in the management of adult patients with stable     chest pain (with or without known CAD); aid in determining when a cardiology consultation is     appropriate; provide guidance for initial noninvasive diagnostic orders (stress testing) and     provide a structured documentation template for the process. Stable patients with cardiac     chest pain require risk stratification, office-based workup, initiation of disease-specific     medications, and subspecialty referral to a cardiologist.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"look up value","display":"appropriate snomed condition"}]}}],"usage":"The Cardiology chest pain (CP) and coronary artery disease (CAD) group of KNARTs are intended to assist primary care providers in the management of adult patients with stable chest pain (with or without known CAD); aid in determining when a cardiology consultation is appropriate; provide guidance for initial noninvasive diagnostic orders (stress testing) and provide a structured documentation template for the process. Stable patients with cardiac chest pain require risk stratification, office-based workup, initiation of disease-specific medications, and subspecialty referral to a cardiologist. This context excludes emergent patients (new/ongoing/unstable pattern CP). Included are those patients with stable CP with or without known CAD, to be considered for evaluation by cardiology.","copyright":"© Copyright Cognitive Medical Systems, Inc. 9444 Waples Street Suite 300 San Diego, CA 92121","author":[{"name":"Bruce Bray MD"},{"name":"Scott Wall MD"},{"name":"Aiden Abidov MD, PhD"}],"relatedArtifact":[{"type":"derived-from","display":"Cardiology: Chest Pain (CP) / Coronary Artery Disease (CAD) Clinical Content White Paper","url":"NEED-A-URL-HERE"},{"type":"justification","display":"Outcome CVD (coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, heart failure)","citation":"Cardiovascular disease          (10-year risk) [Internet].: Framingham Heart Study; cited 2017]. Available from: https://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php.","url":"https://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php"},{"type":"justification","display":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","citation":"Cardiovascular disease          (10-year risk) [Internet].: Framingham Heart Study; cited 2017]. Available from: https://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php.","url":"https://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php"},{"type":"justification","display":"2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","citation":"Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the american college of cardiology/american heart association task force on practice guidelines, and the american association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Thorac Cardiovasc Surg. 2015 March 01;149(3):5.","url":"NEED-A-URL-HERE"},{"type":"justification","display":"ACC/AHA 2002 guideline update for exercise testing: summary article: A report of the American college of cardiology/American heart association task force on practice guidelines (committee to update the 1997 exercise testing guidelines)","citation":"Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: Summary article: A report of the american college of cardiology/american heart association task force on practice guidelines (committee to update the 1997 exercise testing guidelines). Circulation. 2002 October 01;106(14):1883-92.","url":"NEED-A-URL-HERE"},{"type":"justification","display":"LABEL: ASPIRIN 81 MG- aspirin tablet, coated","citation":"Label: ASPIRIN 81 MG- aspirin tablet, coated [Internet].: National Library of Medicine; 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003db4064039-2345-4227-b83d-54dc13a838d3.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003db4064039-2345-4227-b83d-54dc13a838d3"},{"type":"justification","display":"LABEL: CLOPIDOGREL- clopidogrel bisulfate tablet, film coated","citation":"LABEL: CLOPIDOGREL- clopidogrel bisulfate tablet, film coated [Internet].: National Library of Medicine; 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003dedae8df1-caf9-ff72-1304-5ae8b355f8e7.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d7fe85155-bc00-406b-b097-e8aece187a8a"},{"type":"justification","display":"LABEL: LIPITOR- atorvastatin calcium tablet, film coated","citation":"LABEL: LIPITOR- atorvastatin calcium tablet, film coated [Internet].: National Library of Medicine; 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d7fe85155-bc00-406b-b097-e8aece187a8a.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d7fe85155-bc00-406b-b097-e8aece187a8a"},{"type":"justification","display":"LABEL: METOPROLOL SUCCINATE EXTENDED-RELEASE - metoprolol succinate tablet, film coated, extended release","citation":"LABEL: LIPITOR- atorvastatin calcium tablet, film coated [Internet].: National Library of Medicine; 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d7fe85155-bc00-406b-b097-e8aece187a8a.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d2d948600-35d8-4490-983b-918bdce488c8"},{"type":"justification","display":"LABEL: NITROGLYCERIN- nitroglycerin tablet","citation":"LABEL: NITROGLYCERIN- nitroglycerin tablet [Internet].: National Library of Medicine; 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d67bf2a15-b115-47ac-ae28-ce2dafd6b5c9.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d67bf2a15-b115-47ac-ae28-ce2dafd6b5c9"},{"type":"justification","display":"LABEL: SIMVASTATIN - simvastatin tablet","citation":"LABEL: SIMVASTATIN - simvastatin tablet [Internet].: National Library of Medicine; 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d5c1c694c-4b08-469e-b538-08e69df06146.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d5c1c694c-4b08-469e-b538-08e69df06146"},{"type":"justification","display":"Chest Pain Guideline Development Group. NICE guidance. Chest          pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin.","citation":"Skinner JS, Smeeth L, Kendall JM, Adams PC, Timmis A, Chest Pain Guideline Development Group. NICE guidance. chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart. 2010 June 01;96(12):974-8.","url":"http://heart.bmj.com/content/96/12/974.long"}],"library":["#cardiology-chestPain-logic"],"action":[{"action":[{"title":"Consults and Referrals","groupingBehavior":"logical-group","selectionBehavior":"any","action":[{"textEquivalent":"Referral to cardiology to evaluate chest pain (routine)","definitionCanonical":"#referralToCardiologyConsult","dynamicValue":[{"path":"timing.event","expression":{"language":"text/cql","expression":"Now()"}},{"path":"specialty","expression":{"language":"text/cql","expression":"Code \u0027261QM0850X\u0027 from CardiologyChestPainLogic.\"NUCC Provider Taxonomy\" display \u0027Adult Mental Health\u0027"}},{"path":"occurrenceDateTime","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.ServiceRequestFulfillmentTime"}},{"path":"subject","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Patient"}},{"path":"requester.agent","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Practitioner"}},{"path":"reasonCode","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.CardiologyReferralReason"}},{"path":"reasonReference","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.RiskAssessment"}}]},{"title":"Reason for cardiology consultation","definitionCanonical":"#CollectReferralReason"},{"title":"Goal of cardiology consultation","definitionCanonical":"#CardiologyConsultationGoal"}]},{"title":"Medications","description":"Consider the following medications for stable patients to be initiated prior to the cardiology consultation.","action":[{"groupingBehavior":"logical-group","selectionBehavior":"at-most-one"},{"title":"Antianginal Therapy","groupingBehavior":"logical-group","selectionBehavior":"at-most-one","action":[{"textEquivalent":"metoprolol tartrate 25 mg tablet 1 tablet oral 2 time daily","definitionCanonical":"#metoprololTartrate25Prescription","dynamicValue":[{"path":"status","expression":{"language":"text/cql","expression":"\u0027draft\u0027"}},{"path":"patient","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Patient"}},{"path":"prescriber","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Practitioner"}}]},{"textEquivalent":"metoprolol tartrate 50 mg tablet 1 tablet oral 2 time daily","definitionCanonical":"#metoprololTartrate50Prescription","dynamicValue":[{"path":"status","expression":{"language":"text/cql","expression":"\u0027draft\u0027"}},{"path":"patient","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Patient"}},{"path":"prescriber","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Practitioner"}}]},{"textEquivalent":"amlodipine 5  tablet 1 tablet oral  daily","definitionCanonical":"#amlodipinePrescription","dynamicValue":[{"path":"status","expression":{"language":"text/cql","expression":"\u0027draft\u0027"}},{"path":"patient","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Patient"}},{"path":"prescriber","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Practitioner"}}]}]},{"title":"Nitroglycerin","groupingBehavior":"logical-group","selectionBehavior":"at-most-one","action":[{"textEquivalent":"nitroglycerin 0.4 mg tablet sub-lingual every 5 minutes as needed for chest pain; maximum 3 tablets","definitionCanonical":"#nitroglycerinPrescription","dynamicValue":[{"path":"status","expression":{"language":"text/cql","expression":"\u0027draft\u0027"}},{"path":"patient","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Patient"}},{"path":"prescriber","expression":{"language":"text/cql","expression":"CardiologyChestPainLogic.Practitioner"}}]}]}]}]}]}
{"resourceType":"PlanDefinition","id":"KDN5","text":{"status":"additional","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003ctable style\u003d\"width: 100%;\"\u003e\n        \u003ctr\u003e\n          \u003ctd\u003e\n              \u003c!-- link to NCCN image --\u003e\n            \u003cdiv style\u003d\"width: 200px; height: 100px; vertical-align: top;\"\u003eNational Comprehensive Cancer Network\u003c/div\u003e\n          \u003c/td\u003e\n          \u003ctd\u003e\n            \u003ch3\u003eChemotherapy Order Template\u003c/h3\u003e\n            \u003ch1\u003eKidney Cancer\u003c/h1\u003e\n            \u003ch2\u003eGemcitabine/CARBOplatin\u003c/h2\u003e\n          \u003c/td\u003e\n          \u003ctd style\u003d\"text-align: right; vertical-align: top;\"\u003eKDN5\u003c/td\u003e\n        \u003c/tr\u003e\n      \u003c/table\u003e\n      \u003ctable style\u003d\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\"\u003e\n        \u003ctr\u003e\n          \u003ctd style\u003d\"width: 33%; border-right: 1px solid; vertical-align: top\"\u003e\n            \u003ch4\u003eINDICATION:\u003c/h4\u003e\n            \u003cp\u003eMetastatic or Relapsed – Collecting Duct/Medullary Subtypes\u003c/p\u003e\n          \u003c/td\u003e\n          \u003ctd style\u003d\"width: 34%; border-right: 1px solid; vertical-align: top\"\u003e\n            \u003ch4\u003eREFERENCES:\u003c/h4\u003e\n            \u003col\u003e\n              \u003cli\u003e\u003ca href\u003d\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\"\u003eNCCN Guidelines® for Kidney Cancer. V.3.2015.\u003c/a\u003e\u003c/li\u003e\n              \u003cli\u003e\u003ca href\u003d\"http://www.ncbi.nlm.nih.gov/pubmed?term\u003d%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\"\u003eOudard S, et al. \u003cem\u003eJ Urol\u003c/em\u003e. 2007;177(5):1698-702.\u003c/a\u003e\u003csup\u003e\n                  \u003ca href\u003d\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\"\u003ea\u003c/a\u003e\u003c/sup\u003e\n              \u003c/li\u003e\n            \u003c/ol\u003e\n          \u003c/td\u003e\n          \u003ctd style\u003d\"width: 33%; vertical-align: top\"\u003e\n            \u003ch4\u003eNCCN SUPPORTIVE CARE:\u003c/h4\u003e\n            \u003col\u003e\n              \u003cli\u003e\n                \u003ci\u003eEmetic Risk:\u003c/i\u003e\n                \u003ctable\u003e\n                  \u003ctr\u003e\n                    \u003ctd\u003eDay 1\u003c/td\u003e\n                    \u003ctd\u003eModerate\u003c/td\u003e\n                  \u003c/tr\u003e\n                  \u003ctr\u003e\n                    \u003ctd\u003eDay 8\u003c/td\u003e\n                    \u003ctd\u003eLow\u003c/td\u003e\n                  \u003c/tr\u003e\n                \u003c/table\u003e\n              \u003c/li\u003e\n              \u003cli\u003e\n                \u003ci\u003eFever Neutropenia Risk:\u003c/i\u003e\u003cbr/\u003e\n                Refer to \u003ca href\u003d\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\"\u003eNCCN Guidelines for Myeloid Growth Factors. V.2.2014\u003c/a\u003e\n              \u003c/li\u003e\n            \u003c/ol\u003e\n          \u003c/td\u003e\n        \u003c/tr\u003e\n      \u003c/table\u003e\n        \u003c!-- same as the regimen section of the Composition resource only this version is without the style guide notes --\u003e\n      \u003ch4\u003eCHEMOTHERAPY REGIMEN\u003c/h4\u003e\n      \u003cp\u003e\n        \u003ci\u003e21-day cycle for 6 cycles\u003c/i\u003e\n      \u003c/p\u003e\n      \u003cul\u003e\n        \u003cli\u003eGemcitabine 1250 mg/m\u003csup\u003e2\u003c/sup\u003e IV over 30 minutes on Days 1 and 8\u003c/li\u003e\n        \u003cli\u003eCARBOplatin AUC 5 IV over 30 minutes on Day 1\u003c/li\u003e\n      \u003c/ul\u003e\n    \u003c/div\u003e"},"contained":[{"resourceType":"ActivityDefinition","id":"1111","status":"draft","productCodeableConcept":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"gemcitabine"}],"text":"gemcitabine"},"dosage":[{"text":"1250 mg/m² IV over 30 minutes","timing":{"repeat":{"duration":30,"durationUnit":"min"}},"route":{"text":"IV"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"value":1250,"unit":"mg/m²"}}]}]},{"resourceType":"ActivityDefinition","id":"2222","status":"draft","productCodeableConcept":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"}],"text":"CARBOplatin"},"dosage":[{"text":"AUC 5 IV over 30 minutes","timing":{"repeat":{"duration":30,"durationUnit":"min"}},"route":{"text":"IV"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"extension":[{"url":"http://example.org/fhir/AUC-dose","valueInteger":5}]}}]}]}],"identifier":[{"system":"http://example.org/ordertemplates","value":"KDN5"}],"version":"1","title":"Gemcitabine/CARBOplatin","type":{"text":"Chemotherapy Order Template"},"status":"draft","experimental":true,"publisher":"National Comprehensive Cancer Network, Inc.","useContext":[{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"A"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"treamentSetting-or-diseaseStatus"},"valueCodeableConcept":{"text":"Metastatic"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"A"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"disease-or-histology"},"valueCodeableConcept":{"text":"Collecting Duct/Medullary Subtypes"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"A"}],"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"text":"Kidney Cancer"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"B"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"treatmentSetting-or-diseaseStatus"},"valueCodeableConcept":{"text":"Relapsed"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"B"}],"code":{"system":"http://example.org/fhir/CodeSystem/indications","code":"disease-or-histology"},"valueCodeableConcept":{"text":"Collecting Duct/Medullary Subtypes"}},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/usagecontext-group","valueString":"B"}],"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"text":"Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"}}],"copyright":"All rights reserved.","approvalDate":"2016-07-27","lastReviewDate":"2016-07-27","author":[{"name":"Lee Surprenant"}],"relatedArtifact":[{"type":"derived-from","display":"NCCN Guidelines for Kidney Cancer. V.2.2016","url":"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"},{"type":"citation","_type":{"extension":[{"url":"http://example.org/fhir/regimenReferenceType","valueCode":"a"}]},"citation":"Oudard S, et al. J Urol. 2007;177(5):1698-702","url":"http://www.ncbi.nlm.nih.gov/pubmed/17437788"}],"action":[{"selectionBehavior":"exactly-one","action":[{"selectionBehavior":"all","action":[{"groupingBehavior":"sentence-group","selectionBehavior":"exactly-one","action":[{"id":"cycle-definition-1","textEquivalent":"21-day cycle for 6 cycles","timingTiming":{"repeat":{"count":6,"duration":21,"durationUnit":"d"}},"action":[{"id":"action-1","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle","extension":[{"url":"day","valueInteger":1},{"url":"day","valueInteger":8}]}],"textEquivalent":"Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8","definitionCanonical":"#1111"},{"id":"action-2","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle","extension":[{"url":"day","valueInteger":1}]}],"textEquivalent":"CARBOplatin AUC 5 IV over 30 minutes on Day 1","relatedAction":[{"actionId":"action-1","relationship":"concurrent-with-start"}],"definitionCanonical":"#2222"}]}]}]}]}]}
{"resourceType":"PlanDefinition","id":"low-suicide-risk-order-set","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/low-suicide-risk-order-set\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003emmi:low-suicide-risk-order-set\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eLow Suicide Risk Order Set\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003edraft\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eOrders to be applied to a patient characterized as low suicide risk.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003ePurpose: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eThis order set helps ensure consistent application of appropriate orders for the care of low suicide risk patients.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eUsage: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eThis order set should be applied after assessing a patient for suicide risk, when the findings of that assessment indicate the patient has low suicide risk.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003eage\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttps://meshb.nlm.nih.gov\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003eD000328\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003eAdult\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003efocus\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttp://snomed.info/sct\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003e87512008\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003eMild major depression\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003efocus\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttp://snomed.info/sct\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003e40379007\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003eMajor depression, recurrent, mild\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003efocus\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttp://snomed.info/sct\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003e394687007\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003eLow suicide risk\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003efocus\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttp://snomed.info/sct\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003e225337009\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003eSuicide risk assessment\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003euser\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttp://snomed.info/sct\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003e309343006\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003ePhysician\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContext: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr style\u003d\"vertical-align: top;\"\u003e\n               \u003ctd style\u003d\"padding-right: 25px;\"\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003esystem: \u003c/b\u003e\n                     \u003cspan\u003ehttp://terminology.hl7.org/CodeSystem/usage-context-type\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003ecode: \u003c/b\u003e\n                     \u003cspan\u003evenue\u003c/span\u003e\n                  \u003c/p\u003e\n                  \u003cp style\u003d\"padding-left: 25px; margin-top: 5px; margin-bottom: 5px;\"\u003e\n                     \u003cb\u003evalue: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan\u003e\n                        \u003cspan\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003esystem: \u003c/b\u003e\n                                 \u003cspan\u003ehttp://snomed.info/sct\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003ecode: \u003c/b\u003e\n                                 \u003cspan\u003e440655000\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                              \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                                 \u003cb\u003edisplay: \u003c/b\u003e\n                                 \u003cspan\u003eOutpatient environment\u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/p\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eSuicide risk assessment\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eContributor: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003e\n                     \u003cspan\u003eauthor\u003c/span\u003e:\n                  \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 50px; padding-right: 25px;\"\u003eMotive Medical Intelligence\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/suiciderisk-orderset-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003edisplay: \u003c/b\u003e\n                  \u003cspan\u003eSuicideRiskLogic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eSuicide Risk Assessment and Outpatient Management\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eConsults and Referrals\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cspan\u003e\n                           \u003cb\u003eStep: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003etext: \u003c/b\u003e\n                              \u003cspan\u003eRefer to outpatient mental health program for evaluation and treatment of mental health conditions now\u003c/span\u003e\n                              \u003cbr/\u003e\n                           \u003c/span\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003econdition: \u003c/b\u003e\n                              \u003cbr/\u003e\n                              \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                 \u003cb\u003ereference: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 125px;\"\u003e#referralToMentalHealthCare\u003c/span\u003e\n                                 \u003cspan\u003e\n                                    \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                          \u003cb\u003edescription: \u003c/b\u003e\n                                          \u003cspan\u003erefer to primary care mental-health integrated care program for evaluation and treatment of mental health conditions now\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                          \u003cb\u003ecategory: \u003c/b\u003e\n                                          \u003cspan\u003ereferral\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                    \u003c/span\u003e\n                                 \u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                           \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eMedications\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cspan\u003e\n                           \u003cb\u003eStep: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003etitle: \u003c/b\u003e\n                              \u003cspan\u003eFirst-Line Antidepressants\u003c/span\u003e\n                              \u003cbr/\u003e\n                           \u003c/span\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cspan\u003e\n                                 \u003cb\u003eStep: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                    \u003cb\u003etitle: \u003c/b\u003e\n                                    \u003cspan\u003eSelective Serotonin Reuptake Inhibitors (Choose a mazimum of one or document reasons for exception)\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                    \u003cspan\u003e\n                                       \u003cb\u003eStep: \u003c/b\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                          \u003cb\u003etext: \u003c/b\u003e\n                                          \u003cspan\u003ecitalopram 20 mg tablet 1 tablet oral 1 time daily now (30 table; 3 refills)\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                          \u003cb\u003econdition: \u003c/b\u003e\n                                          \u003cbr/\u003e\n                                          \u003cspan style\u003d\"padding-left: 150px;\"\u003e\n                                             \u003cb\u003ereference: \u003c/b\u003e\n                                             \u003cbr/\u003e\n                                             \u003cspan style\u003d\"padding-left: 175px;\"\u003e#citalopramPrescription\u003c/span\u003e\n                                             \u003cspan/\u003e\n                                             \u003cspan\u003e\n                                                \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                                   \u003cbr/\u003e\n                                                   \u003cspan style\u003d\"padding-left: 150px;\"\u003e\n                                                      \u003cb\u003ecategory: \u003c/b\u003e\n                                                      \u003cspan\u003edrug\u003c/span\u003e\n                                                      \u003cbr/\u003e\n                                                   \u003c/span\u003e\n                                                \u003c/span\u003e\n                                             \u003c/span\u003e\n                                             \u003cspan/\u003e\n                                             \u003cspan/\u003e\n                                          \u003c/span\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"/\u003e\n                                    \u003c/span\u003e\n                                    \u003cspan\u003e\n                                       \u003cb\u003eStep: \u003c/b\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                          \u003cb\u003etext: \u003c/b\u003e\n                                          \u003cspan\u003eescitalopram 10 mg tablet 1 tablet oral 1 time daily now (30 tablet; 3 refills)\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"/\u003e\n                                    \u003c/span\u003e\n                                    \u003cspan\u003e\n                                       \u003cb\u003eStep: \u003c/b\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                          \u003cb\u003etext: \u003c/b\u003e\n                                          \u003cspan\u003efluoxetine 20 mg capsule 1 capsule oral 1 time daily now (30 tablet; 3 refills)\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"/\u003e\n                                    \u003c/span\u003e\n                                    \u003cspan\u003e\n                                       \u003cb\u003eStep: \u003c/b\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                          \u003cb\u003etext: \u003c/b\u003e\n                                          \u003cspan\u003eparoxetine 20 mg tablet 1 tablet oral 1 time daily now (30 tablet; 3 refills)\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"/\u003e\n                                    \u003c/span\u003e\n                                    \u003cspan\u003e\n                                       \u003cb\u003eStep: \u003c/b\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                          \u003cb\u003etext: \u003c/b\u003e\n                                          \u003cspan\u003esertraline 50 mg tablet 1 tablet oral 1 time daily now (30 tablet; 3 refills)\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"/\u003e\n                                    \u003c/span\u003e\n                                 \u003c/span\u003e\n                              \u003c/span\u003e\n                              \u003cspan\u003e\n                                 \u003cb\u003eStep: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 125px;\"\u003e\n                                    \u003cb\u003etext: \u003c/b\u003e\n                                    \u003cspan\u003eDopamine Norepinephrine Reuptake Inhibitors (Choose a maximum of one or document reasons for exception)\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 75px;\"/\u003e\n                              \u003c/span\u003e\n                              \u003cspan\u003e\n                                 \u003cb\u003eStep: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                    \u003cb\u003etext: \u003c/b\u003e\n                                    \u003cspan\u003eSerotonin Norepinephrine Reuptake Inhibitors (Choose a maximum of one or doument reasons for exception)\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 75px;\"/\u003e\n                              \u003c/span\u003e\n                              \u003cspan\u003e\n                                 \u003cb\u003eStep: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                    \u003cb\u003etext: \u003c/b\u003e\n                                    \u003cspan\u003eNorepinephrine-Serotonin Modulators (Choose a maximum of one or document reasons for exception)\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"/\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"contained":[{"resourceType":"ActivityDefinition","id":"referralToMentalHealthCare","status":"draft","description":"refer to primary care mental-health integrated care program for evaluation and treatment of mental health conditions now","kind":"ServiceRequest","code":{"coding":[{"system":"http://snomed.info/sct","code":"306206005"}],"text":"Referral to service (procedure)"},"timingTiming":{"_event":[{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-expression","valueExpression":{"language":"text/cql","expression":"Now()"}}]}]},"participant":[{"type":"practitioner"}]},{"resourceType":"ActivityDefinition","id":"citalopramPrescription","status":"draft","kind":"MedicationRequest","productReference":{"reference":"#citalopramMedication"},"dosage":[{"text":"1 tablet oral 1 time daily","timing":{"repeat":{"frequency":1,"period":1,"periodUnit":"d"}},"route":{"coding":[{"code":"26643006","display":"Oral route (qualifier value)"}],"text":"Oral route (qualifier value)"},"doseAndRate":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/dose-rate-type","code":"ordered","display":"Ordered"}]},"doseQuantity":{"value":1,"unit":"{tbl}"}}]}],"dynamicValue":[{"path":"dispenseRequest.numberOfRepeatsAllowed","expression":{"language":"text/cql","expression":"3"}},{"path":"dispenseRequest.quantity","expression":{"language":"text/cql","expression":"30 \u0027{tbl}\u0027"}}]},{"resourceType":"Medication","id":"citalopramMedication","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"200371"}],"text":"citalopram"},"doseForm":{"coding":[{"system":"http://snomed.info/sct","code":"385055001","display":"Tablet dose form"}],"text":"Tablet dose form"},"ingredient":[{"item":{"reference":{"reference":"#citalopramSubstance"}},"strengthRatio":{"numerator":{"value":20,"unit":"mg"},"denominator":{"value":1,"unit":"{tbl}"}}}]},{"resourceType":"Substance","id":"citalopramSubstance","code":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2556"}],"text":"citalopram"}}],"url":"http://motivemi.com/artifacts/PlanDefinition/low-suicide-risk-order-set","identifier":[{"use":"official","system":"http://motivemi.com/artifacts","value":"mmi:low-suicide-risk-order-set"}],"version":"1.0.0","name":"LowSuicideRiskOrderSet","title":"Low Suicide Risk Order Set","status":"active","experimental":true,"date":"2015-08-15","publisher":"Motive Medical Intelligence","contact":[{"telecom":[{"system":"phone","value":"415-362-4007","use":"work"},{"system":"email","value":"info@motivemi.com","use":"work"}]}],"description":"Orders to be applied to a patient characterized as low suicide risk.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"age"},"valueCodeableConcept":{"coding":[{"system":"https://meshb.nlm.nih.gov","code":"D000328","display":"Adult"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"87512008","display":"Mild major depression"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"40379007","display":"Major depression, recurrent, mild"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"394687007","display":"Low suicide risk"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"225337009","display":"Suicide risk assessment"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"user"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"309343006","display":"Physician"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"venue"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"440655000","display":"Outpatient environment"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"This order set helps ensure consistent application of appropriate orders for the care of low suicide risk patients.","usage":"This order set should be applied after assessing a patient for suicide risk, when the findings of that assessment indicate the patient has low suicide risk.","copyright":"© Copyright 2016 Motive Medical Intelligence. All rights reserved.","approvalDate":"2016-03-12","lastReviewDate":"2016-08-15","effectivePeriod":{"start":"2016-01-01","end":"2017-12-31"},"topic":[{"text":"Suicide risk assessment"}],"author":[{"name":"Motive Medical Intelligence","telecom":[{"system":"phone","value":"415-362-4007","use":"work"},{"system":"email","value":"info@motivemi.com","use":"work"}]}],"relatedArtifact":[{"type":"derived-from","display":"Practice Guideline for the Treatment of Patients with Major Depressive Disorder","url":"http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf"},{"type":"composed-of","resource":"http://example.org/fhir/ActivityDefinition/referralPrimaryCareMentalHealth"},{"type":"composed-of","resource":"http://example.org/fhir/ActivityDefinition/citalopramPrescription"}],"library":["http://example.org/fhir/Library/suiciderisk-orderset-logic"],"action":[{"title":"Suicide Risk Assessment and Outpatient Management","action":[{"title":"Consults and Referrals","groupingBehavior":"logical-group","selectionBehavior":"any","action":[{"textEquivalent":"Refer to outpatient mental health program for evaluation and treatment of mental health conditions now","definitionCanonical":"#referralToMentalHealthCare","dynamicValue":[{"path":"timing.event","expression":{"language":"text/cql","expression":"Now()"}},{"path":"specialty","expression":{"language":"text/cql","expression":"Code \u0027261QM0850X\u0027 from SuicideRiskLogic.\"NUCC Provider Taxonomy\" display \u0027Adult Mental Health\u0027"}},{"path":"occurrenceDateTime","expression":{"language":"text/cql","expression":"SuicideRiskLogic.ServiceRequestFulfillmentTime"}},{"path":"subject","expression":{"language":"text/cql","expression":"SuicideRiskLogic.Patient"}},{"path":"requester.agent","expression":{"language":"text/cql","expression":"SuicideRiskLogic.Practitioner"}},{"path":"reasonCode","expression":{"language":"text/cql","expression":"SuicideRiskLogic.RiskAssessmentScore"}},{"path":"reasonReference","expression":{"language":"text/cql","expression":"SuicideRiskLogic.RiskAssessment"}}]}]},{"title":"Medications","groupingBehavior":"logical-group","selectionBehavior":"at-most-one","action":[{"title":"First-Line Antidepressants","documentation":[{"type":"citation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"high"}],"text":"High Quality"}}],"contentType":"text/html","url":"http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf","title":"Practice Guideline for the Treatment of Patients with Major Depressive Disorder"}}],"groupingBehavior":"logical-group","selectionBehavior":"at-most-one","action":[{"title":"Selective Serotonin Reuptake Inhibitors (Choose a mazimum of one or document reasons for exception)","documentation":[{"type":"citation","document":{"contentType":"text/html","url":"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid\u003d6daeb45c-451d-b135-bf8f-2d6dff4b6b01","title":"National Library of Medicine. DailyMed website. CITALOPRAM- citalopram hydrobromide tablet, film coated."}}],"groupingBehavior":"logical-group","selectionBehavior":"at-most-one","action":[{"textEquivalent":"citalopram 20 mg tablet 1 tablet oral 1 time daily now (30 table; 3 refills)","definitionCanonical":"#citalopramPrescription","dynamicValue":[{"path":"status","expression":{"language":"text/cql","expression":"\u0027draft\u0027"}},{"path":"patient","expression":{"language":"text/cql","expression":"SuicideRiskLogic.Patient"}},{"path":"prescriber","expression":{"language":"text/cql","expression":"SuicideRiskLogic.Practitioner"}},{"path":"reasonCode","expression":{"language":"text/cql","expression":"SuicideRiskLogic.RiskAssessmentScore"}},{"path":"reasonReference","expression":{"language":"text/cql","expression":"SuicideRiskLogic.RiskAssessment"}}]},{"textEquivalent":"escitalopram 10 mg tablet 1 tablet oral 1 time daily now (30 tablet; 3 refills)"},{"textEquivalent":"fluoxetine 20 mg capsule 1 capsule oral 1 time daily now (30 tablet; 3 refills)"},{"textEquivalent":"paroxetine 20 mg tablet 1 tablet oral 1 time daily now (30 tablet; 3 refills)"},{"textEquivalent":"sertraline 50 mg tablet 1 tablet oral 1 time daily now (30 tablet; 3 refills)"}]},{"textEquivalent":"Dopamine Norepinephrine Reuptake Inhibitors (Choose a maximum of one or document reasons for exception)"},{"textEquivalent":"Serotonin Norepinephrine Reuptake Inhibitors (Choose a maximum of one or doument reasons for exception)"},{"textEquivalent":"Norepinephrine-Serotonin Modulators (Choose a maximum of one or document reasons for exception)"}]}]}]}]}
{"resourceType":"PlanDefinition","id":"exclusive-breastfeeding-intervention-01","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/exclusive-breastfeeding-intervention-01\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003eexclusive-breastfeeding-intervention-01\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive Breastfeeding Intervention-01\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eactive\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by ensuring that an appropriate breastfeeding readiness assessment order is created if necessary.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eExclusive Breastfeeding\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/library-exclusive-breastfeeding-cds-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eMother should be administered a breastfeeding readiness assessment.\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eShould Create Assessment Order\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eCreate the breastfeeding readiness assessment order.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etext: \u003c/b\u003e\n                        \u003cspan\u003eAdminister a breastfeeding readiness assessment.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eNotify the provider to sign the order.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003etext: \u003c/b\u003e\n                        \u003cspan\u003eA Breastfeeding Readiness Assessment is recommended, please authorize or reject the order.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"identifier":[{"use":"official","value":"exclusive-breastfeeding-intervention-01"}],"version":"1.0.0","title":"Exclusive Breastfeeding Intervention-01","status":"active","date":"2015-03-08","description":"Exclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by ensuring that an appropriate breastfeeding readiness assessment order is created if necessary.","topic":[{"text":"Exclusive Breastfeeding"}],"relatedArtifact":[{"type":"derived-from","resource":"http://example.org/fhir/Measure/measure-exclusive-breastfeeding"}],"library":["http://example.org/fhir/Library/library-exclusive-breastfeeding-cds-logic"],"action":[{"title":"Mother should be administered a breastfeeding readiness assessment.","trigger":[{"type":"named-event","name":"Admission"},{"type":"named-event","name":"Birth"},{"type":"named-event","name":"Infant Transfer to Recovery"},{"type":"named-event","name":"Transfer to Post-Partum"}],"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Create Assessment Order"}}],"action":[{"title":"Create the breastfeeding readiness assessment order.","textEquivalent":"Administer a breastfeeding readiness assessment.","type":{"coding":[{"code":"create"}]},"dynamicValue":[{"path":"/","expression":{"language":"text/cql","expression":"Create Breastfeeding Risk Assessment"}}]},{"title":"Notify the provider to sign the order.","textEquivalent":"A Breastfeeding Readiness Assessment is recommended, please authorize or reject the order.","type":{"coding":[{"code":"create"}]},"dynamicValue":[{"path":"/","expression":{"language":"text/cql","expression":"Communication Request to Provider"}}]}]}]}
{"resourceType":"PlanDefinition","id":"exclusive-breastfeeding-intervention-02","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/exclusive-breastfeeding-intervention-02\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003eexclusive-breastfeeding-intervention-02\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive Breastfeeding Intervention-02\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eactive\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by notifying the provider to sign the breastmilk feeding readiness assessment order, if necessary.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eExclusive Breastfeeding\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/library-exclusive-breastfeeding-cds-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eMother should be administered a breastfeeding readiness assessment.\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eShould Notify Provider to Sign Assessment Order\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eNotify the provider to sign the order.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etext: \u003c/b\u003e\n                        \u003cspan\u003eA Breastfeeding Readiness Assessment is recommended, please authorize or reject the order.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"identifier":[{"use":"official","value":"exclusive-breastfeeding-intervention-02"}],"version":"1.0.0","title":"Exclusive Breastfeeding Intervention-02","status":"active","date":"2015-03-08","description":"Exclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by notifying the provider to sign the breastmilk feeding readiness assessment order, if necessary.","topic":[{"text":"Exclusive Breastfeeding"}],"relatedArtifact":[{"type":"derived-from","resource":"http://example.org/fhir/Measure/measure-exclusive-breastfeeding"}],"library":["http://example.org/fhir/Library/library-exclusive-breastfeeding-cds-logic"],"action":[{"title":"Mother should be administered a breastfeeding readiness assessment.","trigger":[{"type":"named-event","name":"Admission"},{"type":"named-event","name":"Birth"},{"type":"named-event","name":"Infant Transfer to Recovery"},{"type":"named-event","name":"Transfer to Post-Partum"}],"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Notify Provider to Sign Assessment Order"}}],"action":[{"title":"Notify the provider to sign the order.","textEquivalent":"A Breastfeeding Readiness Assessment is recommended, please authorize or reject the order.","type":{"coding":[{"code":"create"}]},"dynamicValue":[{"path":"/","expression":{"language":"text/cql","expression":"Communication Request to Provider"}}]}]}]}
{"resourceType":"PlanDefinition","id":"exclusive-breastfeeding-intervention-03","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/exclusive-breastfeeding-intervention-03\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003eexclusive-breastfeeding-intervention-03\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive Breastfeeding Intervention-03\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eactive\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by notifying the charge and/or bedside nurse to perform the breastfeeding readiness assessment.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eExclusive Breastfeeding\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/library-exclusive-breastfeeding-cds-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eMother should be administered a breastfeeding readiness assessment.\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eShould Notify Nurse to Perform Assessment\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eNotify the charge nurse to perform the assessment.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etext: \u003c/b\u003e\n                        \u003cspan\u003eA Breastfeeding Readiness Assessment is recommended, please administer the assessment.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eNotify the bedside nurse to perform the assessment.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003etext: \u003c/b\u003e\n                        \u003cspan\u003eA Breastfeeding Readiness Assessment is recommended, please administer the assessment.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"identifier":[{"use":"official","value":"exclusive-breastfeeding-intervention-03"}],"version":"1.0.0","title":"Exclusive Breastfeeding Intervention-03","status":"active","date":"2015-03-08","description":"Exclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by notifying the charge and/or bedside nurse to perform the breastfeeding readiness assessment.","topic":[{"text":"Exclusive Breastfeeding"}],"relatedArtifact":[{"type":"derived-from","resource":"http://example.org/fhir/Measure/measure-exclusive-breastfeeding"}],"library":["http://example.org/fhir/Library/library-exclusive-breastfeeding-cds-logic"],"action":[{"title":"Mother should be administered a breastfeeding readiness assessment.","trigger":[{"type":"named-event","name":"Admission"},{"type":"named-event","name":"Birth"},{"type":"named-event","name":"Infant Transfer to Recovery"},{"type":"named-event","name":"Transfer to Post-Partum"}],"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Notify Nurse to Perform Assessment"}}],"action":[{"title":"Notify the charge nurse to perform the assessment.","textEquivalent":"A Breastfeeding Readiness Assessment is recommended, please administer the assessment.","type":{"coding":[{"code":"create"}]},"dynamicValue":[{"path":"/","expression":{"language":"text/cql","expression":"Communication Request to Charge Nurse"}}]},{"title":"Notify the bedside nurse to perform the assessment.","textEquivalent":"A Breastfeeding Readiness Assessment is recommended, please administer the assessment.","type":{"coding":[{"code":"create"}]},"dynamicValue":[{"path":"/","expression":{"language":"text/cql","expression":"Communication Request to Bedside Nurse"}}]}]}]}
{"resourceType":"PlanDefinition","id":"exclusive-breastfeeding-intervention-04","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/exclusive-breastfeeding-intervention-04\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003eexclusive-breastfeeding-intervention-04\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive Breastfeeding Intervention-04\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eactive\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by creating a lactation consult for the mother if appropriate.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eExclusive Breastfeeding\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/library-exclusive-breastfeeding-cds-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eMother should be referred to a lactation specialist for consultation.\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eShould Create Lactation Consult\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etitle: \u003c/b\u003e\n                        \u003cspan\u003eCreate a lactation consult request.\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003etext: \u003c/b\u003e\n                        \u003cspan\u003eCreate a lactation consult request\u003c/span\u003e\n                        \u003cbr/\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"identifier":[{"use":"official","value":"exclusive-breastfeeding-intervention-04"}],"version":"1.0.0","title":"Exclusive Breastfeeding Intervention-04","status":"active","date":"2015-03-08","description":"Exclusive breastfeeding intervention intended to improve outcomes for exclusive breastmilk feeding of newborns by creating a lactation consult for the mother if appropriate.","topic":[{"text":"Exclusive Breastfeeding"}],"relatedArtifact":[{"type":"derived-from","resource":"http://example.org/fhir/Measure/measure-exclusive-breastfeeding"}],"library":["http://example.org/fhir/Library/library-exclusive-breastfeeding-cds-logic"],"action":[{"title":"Mother should be referred to a lactation specialist for consultation.","trigger":[{"type":"named-event","name":"Admission"},{"type":"named-event","name":"Birth"},{"type":"named-event","name":"Infant Transfer to Recovery"},{"type":"named-event","name":"Transfer to Post-Partum"}],"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Create Lactation Consult"}}],"action":[{"title":"Create a lactation consult request.","textEquivalent":"Create a lactation consult request","type":{"coding":[{"code":"create"}]},"dynamicValue":[{"path":"/","expression":{"language":"text/cql","expression":"Create Lactation Consult Request"}}]}]}]}
{"resourceType":"PlanDefinition","id":"opioidcds-04","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: opioidcds-04\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-04\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: cdc-opioid-guidance (OFFICIAL)\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1.0\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: cdc-opioid-04\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: CDC Opioid Prescribing Guideline Recommendation #4\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eECA Rule\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: draft\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2018-03-19\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Centers for Disease Control and Prevention (CDC)\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003ejurisdiction\u003c/b\u003e: \u003cspan\u003eUnited States of America\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epurpose\u003c/b\u003e: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: Providers should use caution when prescribing extended-release/long-acting (ER/LA) opioids as they carry a higher risk and negligible benefit compared to immediate-release opioids.\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © CDC 2016+.\u003c/p\u003e\u003cp\u003e\u003cb\u003etopic\u003c/b\u003e: \u003cspan\u003eOpioid Prescribing\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003ehttp://example.org/fhir/Library/opioidcds-recommendation-04\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Extended-release opioid prescription triggered.\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Checking if the trigger prescription meets the inclusion criteria for recommendation #4 workflow.\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003etrigger\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003egroupingBehavior\u003c/b\u003e: visual-group\u003c/p\u003e\u003cp\u003e\u003cb\u003eselectionBehavior\u003c/b\u003e: exactly-one\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.title\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.description\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: activity.extension\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003ch3\u003eActions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWill precribe immediate release\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eRisk of overdose carefully considered and outweighed by benefit; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eN/A - see comment; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"url":"http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-04","identifier":[{"use":"official","value":"cdc-opioid-guidance"}],"version":"0.1.0","name":"cdc-opioid-04","title":"CDC Opioid Prescribing Guideline Recommendation #4","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule","display":"ECA Rule"}]},"status":"draft","date":"2018-03-19","publisher":"Centers for Disease Control and Prevention (CDC)","description":"When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182888003","display":"Medication requested (situation)"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"82423001","display":"Chronic pain (finding)"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US","display":"United States of America"}]}],"purpose":"CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.","usage":"Providers should use caution when prescribing extended-release/long-acting (ER/LA) opioids as they carry a higher risk and negligible benefit compared to immediate-release opioids.","copyright":"© CDC 2016+.","topic":[{"text":"Opioid Prescribing"}],"author":[{"name":"Kensaku Kawamoto, MD, PhD, MHS"},{"name":"Bryn Rhodes"},{"name":"Floyd Eisenberg, MD, MPH"},{"name":"Robert McClure, MD, MPH"}],"relatedArtifact":[{"type":"documentation","display":"CDC guideline for prescribing opioids for chronic pain","url":"https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016#420"},{"type":"documentation","display":"MME Conversion Tables","url":"https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf"}],"library":["http://example.org/fhir/Library/opioidcds-recommendation-04"],"action":[{"title":"Extended-release opioid prescription triggered.","description":"Checking if the trigger prescription meets the inclusion criteria for recommendation #4 workflow.","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"trigger":[{"type":"named-event","name":"medication-prescribe"}],"condition":[{"kind":"applicability","expression":{"description":"Check whether the opioid prescription for the existing patient is extended-release without any opioids-with-abuse-potential prescribed in the past 90 days.","language":"text/cql","expression":"Inclusion Criteria"}}],"groupingBehavior":"visual-group","selectionBehavior":"exactly-one","dynamicValue":[{"path":"action.title","expression":{"language":"text/cql","expression":"Get Summary"}},{"path":"action.description","expression":{"language":"text/cql","expression":"Get Detail"}},{"path":"activity.extension","expression":{"language":"text/cql","expression":"Get Indicator"}}],"action":[{"description":"Will precribe immediate release"},{"description":"Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo"},{"description":"N/A - see comment; snooze 3 mo"}]}]}
{"resourceType":"PlanDefinition","id":"opioidcds-05","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: opioidcds-05\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-05\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: cdc-opioid-guidance (OFFICIAL)\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1.0\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: cdc-opioid-05\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: CDC Opioid Prescribing Guideline Recommendation #5\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eECA Rule\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: draft\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2017-04-23\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Centers for Disease Control and Prevention (CDC)\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: When opioids are started, providers should prescribe the lowest effective dosage.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003ejurisdiction\u003c/b\u003e: \u003cspan\u003eUnited States of America\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epurpose\u003c/b\u003e: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: Providers should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when considering increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to \u0026gt;90 MME/day\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © CDC 2016+.\u003c/p\u003e\u003cp\u003e\u003cb\u003etopic\u003c/b\u003e: \u003cspan\u003eOpioid Prescribing\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003ehttp://example.org/fhir/Library/opioidcds-recommendation-05\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: High risk for opioid overdose.\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Total morphine milligram equivalent (MME) exceeds recommended amount. Taper to less than 50.\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003etrigger\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003egroupingBehavior\u003c/b\u003e: visual-group\u003c/p\u003e\u003cp\u003e\u003cb\u003eselectionBehavior\u003c/b\u003e: exactly-one\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.title\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.description\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: activity.extension\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003ch3\u003eActions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWill reduce dosage\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eRisk of overdose carefully considered and outweighed by benefit; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eAcute pain; snooze 1 mo\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eN/A - see comment (will be reviewed by medical director); snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"url":"http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-05","identifier":[{"use":"official","value":"cdc-opioid-guidance"}],"version":"0.1.0","name":"cdc-opioid-05","title":"CDC Opioid Prescribing Guideline Recommendation #5","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule","display":"ECA Rule"}]},"status":"draft","date":"2017-04-23","publisher":"Centers for Disease Control and Prevention (CDC)","description":"When opioids are started, providers should prescribe the lowest effective dosage.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182888003","display":"Medication requested (situation)"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"82423001","display":"Chronic pain (finding)"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US","display":"United States of America"}]}],"purpose":"CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.","usage":"Providers should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when considering increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to \u003e90 MME/day","copyright":"© CDC 2016+.","topic":[{"text":"Opioid Prescribing"}],"author":[{"name":"Kensaku Kawamoto, MD, PhD, MHS"},{"name":"Bryn Rhodes"},{"name":"Floyd Eisenberg, MD, MPH"},{"name":"Robert McClure, MD, MPH"}],"relatedArtifact":[{"type":"documentation","display":"CDC guideline for prescribing opioids for chronic pain","url":"https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016#420"},{"type":"documentation","display":"MME Conversion Tables","url":"https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf"}],"library":["http://example.org/fhir/Library/opioidcds-recommendation-05"],"action":[{"title":"High risk for opioid overdose.","description":"Total morphine milligram equivalent (MME) exceeds recommended amount. Taper to less than 50.","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"trigger":[{"type":"named-event","name":"medication-prescribe"}],"condition":[{"kind":"applicability","expression":{"description":"Is total MME \u003e\u003d 50?","language":"text/cql","expression":"Is MME 50 Or More?"}}],"groupingBehavior":"visual-group","selectionBehavior":"exactly-one","dynamicValue":[{"path":"action.title","expression":{"language":"text/cql","expression":"getSummary"}},{"path":"action.description","expression":{"language":"text/cql","expression":"getDetail"}},{"path":"activity.extension","expression":{"language":"text/cql","expression":"getIndicator"}}],"action":[{"description":"Will reduce dosage"},{"description":"Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo"},{"description":"Acute pain; snooze 1 mo"},{"description":"N/A - see comment (will be reviewed by medical director); snooze 3 mo"}]}]}
{"resourceType":"PlanDefinition","id":"opioidcds-07","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: opioidcds-07\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-07\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: cdc-opioid-guidance (OFFICIAL)\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1.0\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: cdc-opioid-07\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: CDC Opioid Prescribing Guideline Recommendation #7\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eECA Rule\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: draft\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2018-03-19\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Centers for Disease Control and Prevention (CDC)\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003ejurisdiction\u003c/b\u003e: \u003cspan\u003eUnited States of America\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epurpose\u003c/b\u003e: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © CDC 2016+.\u003c/p\u003e\u003cp\u003e\u003cb\u003etopic\u003c/b\u003e: \u003cspan\u003eOpioid Prescribing\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003ehttp://example.org/fhir/Library/opioidcds-recommendation-07\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Existing patient should be evaluated for risk of continued opioid therapy.\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Checking if the trigger prescription meets the inclusion criteria for recommendation #7 workflow.\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003etrigger\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003egroupingBehavior\u003c/b\u003e: visual-group\u003c/p\u003e\u003cp\u003e\u003cb\u003eselectionBehavior\u003c/b\u003e: exactly-one\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.title\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.description\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.extension\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003ch3\u003eActions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWill schedule assessment of risk for opioid use for the patient\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eRisk of overdose carefully considered and outweighed by benefit; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eN/A - see comment; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"url":"http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-07","identifier":[{"use":"official","value":"cdc-opioid-guidance"}],"version":"0.1.0","name":"cdc-opioid-07","title":"CDC Opioid Prescribing Guideline Recommendation #7","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule","display":"ECA Rule"}]},"status":"draft","date":"2018-03-19","publisher":"Centers for Disease Control and Prevention (CDC)","description":"Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182888003","display":"Medication requested (situation)"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"82423001","display":"Chronic pain (finding)"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US","display":"United States of America"}]}],"purpose":"CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.","usage":"If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.","copyright":"© CDC 2016+.","topic":[{"text":"Opioid Prescribing"}],"author":[{"name":"Kensaku Kawamoto, MD, PhD, MHS"},{"name":"Bryn Rhodes"},{"name":"Floyd Eisenberg, MD, MPH"},{"name":"Robert McClure, MD, MPH"}],"relatedArtifact":[{"type":"documentation","display":"CDC guideline for prescribing opioids for chronic pain","url":"https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016#420"},{"type":"documentation","display":"MME Conversion Tables","url":"https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf"}],"library":["http://example.org/fhir/Library/opioidcds-recommendation-07"],"action":[{"title":"Existing patient should be evaluated for risk of continued opioid therapy.","description":"Checking if the trigger prescription meets the inclusion criteria for recommendation #7 workflow.","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"trigger":[{"type":"named-event","name":"medication-prescribe"}],"condition":[{"kind":"applicability","expression":{"description":"Check whether the existing patient, without an end of life condition or risk assessment in the past 90 days, has taken an opioid-with-abuse-potential for 7 of the past 10 days or 63 of the past 90 days.","language":"text/cql","expression":"Inclusion Criteria"}}],"groupingBehavior":"visual-group","selectionBehavior":"exactly-one","dynamicValue":[{"path":"action.title","expression":{"language":"text/cql","expression":"Get Summary"}},{"path":"action.description","expression":{"language":"text/cql","expression":"Get Detail"}},{"path":"action.extension","expression":{"language":"text/cql","expression":"Get Indicator"}}],"action":[{"description":"Will schedule assessment of risk for opioid use for the patient"},{"description":"Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo"},{"description":"N/A - see comment; snooze 3 mo"}]}]}
{"resourceType":"PlanDefinition","id":"opioidcds-08","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: opioidcds-08\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-08\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: cdc-opioid-guidance (OFFICIAL)\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1.0\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: cdc-opioid-08\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: CDC Opioid Prescribing Guideline Recommendation #8\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eECA Rule\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: draft\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2018-03-19\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Centers for Disease Control and Prevention (CDC)\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003ejurisdiction\u003c/b\u003e: \u003cspan\u003eUnited States of America\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epurpose\u003c/b\u003e: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © CDC 2016+.\u003c/p\u003e\u003cp\u003e\u003cb\u003etopic\u003c/b\u003e: \u003cspan\u003eOpioid Prescribing\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003ehttp://example.org/fhir/Library/opioidcds-recommendation-08\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Existing patient exhibits risk factors for opioid-related harms.\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Checking if the trigger prescription meets the inclusion criteria for recommendation #8 workflow.\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003etrigger\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003egroupingBehavior\u003c/b\u003e: visual-group\u003c/p\u003e\u003cp\u003e\u003cb\u003eselectionBehavior\u003c/b\u003e: exactly-one\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.description\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.title\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.extension\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003ch3\u003eActions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWill offer Naloxone instead\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eRisk of overdose carefully considered and outweighed by benefit; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eN/A - see comment; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"url":"http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-08","identifier":[{"use":"official","value":"cdc-opioid-guidance"}],"version":"0.1.0","name":"cdc-opioid-08","title":"CDC Opioid Prescribing Guideline Recommendation #8","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule","display":"ECA Rule"}]},"status":"draft","date":"2018-03-19","publisher":"Centers for Disease Control and Prevention (CDC)","description":"Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182888003","display":"Medication requested (situation)"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"82423001","display":"Chronic pain (finding)"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US","display":"United States of America"}]}],"purpose":"CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.","usage":"Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.","copyright":"© CDC 2016+.","topic":[{"text":"Opioid Prescribing"}],"author":[{"name":"Kensaku Kawamoto, MD, PhD, MHS"},{"name":"Bryn Rhodes"},{"name":"Floyd Eisenberg, MD, MPH"},{"name":"Robert McClure, MD, MPH"}],"relatedArtifact":[{"type":"documentation","display":"CDC guideline for prescribing opioids for chronic pain","url":"https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016#420"},{"type":"documentation","display":"MME Conversion Tables","url":"https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf"}],"library":["http://example.org/fhir/Library/opioidcds-recommendation-08"],"action":[{"title":"Existing patient exhibits risk factors for opioid-related harms.","description":"Checking if the trigger prescription meets the inclusion criteria for recommendation #8 workflow.","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"trigger":[{"type":"named-event","name":"medication-prescribe"}],"condition":[{"kind":"applicability","expression":{"description":"Check whether the existing patient exhibits risk factors for opioid-related harms, such as concurrent use with benzodiazepine, a history of substance abuse, and/or an average MME greater than 50 mg/day.","language":"text/cql","expression":"Inclusion Criteria"}}],"groupingBehavior":"visual-group","selectionBehavior":"exactly-one","dynamicValue":[{"path":"action.description","expression":{"language":"text/cql","expression":"Get Detail"}},{"path":"action.title","expression":{"language":"text/cql","expression":"Get Summary"}},{"path":"action.extension","expression":{"language":"text/cql","expression":"Get Indicator"}}],"action":[{"description":"Will offer Naloxone instead"},{"description":"Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo"},{"description":"N/A - see comment; snooze 3 mo"}]}]}
{"resourceType":"PlanDefinition","id":"opioidcds-10","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: opioidcds-10\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-10\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: cdc-opioid-guidance (OFFICIAL)\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1.0\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: cdc-opioid-10\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: CDC Opioid Prescribing Guideline Recommendation #10\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eECA Rule\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: draft\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2017-04-23\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Centers for Disease Control and Prevention (CDC)\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: When prescribing opioids for chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003ejurisdiction\u003c/b\u003e: \u003cspan\u003eUnited States of America\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epurpose\u003c/b\u003e: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: Providers should be aware if patients are taking other prescription drugs or illicit drugs that might increase their risk of an overdose.\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © CDC 2016+.\u003c/p\u003e\u003cp\u003e\u003cb\u003etopic\u003c/b\u003e: \u003cspan\u003eOpioid Prescribing\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003ehttp://example.org/fhir/Library/opioidcds-recommendation-10\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Annual Urine Screening Check\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Patient has not had a urine screening in the past 12 months\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003etrigger\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eDynamicValues\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003ePath\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eactivity.extension\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eActions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWill perform urine screening\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eNot for chronic pain management. Snooze 3 months\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Positive Urine Screening Check\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Patient has a urine screening testing positive for either unprescribed opioids or illicit drugs in the past 12 months\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"url":"http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-10","identifier":[{"use":"official","value":"cdc-opioid-guidance"}],"version":"0.1.0","name":"cdc-opioid-10","title":"CDC Opioid Prescribing Guideline Recommendation #10","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule","display":"ECA Rule"}]},"status":"draft","date":"2017-04-23","publisher":"Centers for Disease Control and Prevention (CDC)","description":"When prescribing opioids for chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182888003","display":"Medication requested (situation)"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"82423001","display":"Chronic pain (finding)"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US","display":"United States of America"}]}],"purpose":"CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.","usage":"Providers should be aware if patients are taking other prescription drugs or illicit drugs that might increase their risk of an overdose.","copyright":"© CDC 2016+.","topic":[{"text":"Opioid Prescribing"}],"author":[{"name":"Kensaku Kawamoto, MD, PhD, MHS"},{"name":"Bryn Rhodes"},{"name":"Floyd Eisenberg, MD, MPH"},{"name":"Robert McClure, MD, MPH"}],"relatedArtifact":[{"type":"documentation","display":"CDC guideline for prescribing opioids for chronic pain","url":"https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016#420"}],"library":["http://example.org/fhir/Library/opioidcds-recommendation-10"],"action":[{"title":"Annual Urine Screening Check","description":"Patient has not had a urine screening in the past 12 months","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"trigger":[{"type":"named-event","name":"medication-prescribe"}],"condition":[{"kind":"applicability","expression":{"description":"Patient has not had a urine screening in the past 12 months","language":"text/cql","expression":"No Screenings in Past Year"}}],"dynamicValue":[{"path":"activity.extension","expression":{"language":"text/cql","expression":"Get Indicator"}}],"action":[{"description":"Will perform urine screening"},{"description":"Not for chronic pain management. Snooze 3 months"}]},{"title":"Positive Urine Screening Check","description":"Patient has a urine screening testing positive for either unprescribed opioids or illicit drugs in the past 12 months","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"condition":[{"kind":"applicability","expression":{"description":"Patient has a positive urine screening in the past 12 months","language":"text/cql","expression":"Has Positive Screening?"}}],"action":[{"title":"Unprescribed Opioids Found In Urine Screening","description":"Patient has a positive urine screening in the past 12 months for opioid(s), which is not prescribed","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"condition":[{"kind":"applicability","expression":{"description":"Patient has a positive urine screening in the past 12 months for opioid(s), which is not prescribed","language":"text/cql","expression":"Has Unprescribed Opioids?"}}],"dynamicValue":[{"path":"activity.extension","expression":{"language":"text/cql","expression":"Get Indicator"}},{"path":"action.description","expression":{"language":"text/cql","expression":"Inconsistent Unprescribed Opioids"}}],"action":[{"description":"Not for chronic pain management. Snooze 3 months"}]},{"title":"Prescribed Opioids Not Found In Urine Screening","description":"Patient has a positive urine screening in the past 12 months, which does not include prescribed opioids","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"condition":[{"kind":"applicability","expression":{"description":"Patient has a positive urine screening in the past 12 months, which does not include prescribed opioids","language":"text/cql","expression":"Has Missing Opioids?"}}],"dynamicValue":[{"path":"activity.extension","expression":{"language":"text/cql","expression":"Get Indicator"}},{"path":"action.description","expression":{"language":"text/cql","expression":"Inconsistent Missing Opioids"}}]},{"title":"Illicit Drugs Found In Urine Screening","description":"Patient has a positive urine screening in the past 12 months for illicit drugs","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"condition":[{"kind":"applicability","expression":{"description":"Patient has a positive urine screening in the past 12 months for illicit drugs","language":"text/cql","expression":"Has Illicit Drugs in Screening?"}}],"dynamicValue":[{"path":"activity.extension","expression":{"language":"text/cql","expression":"Get Indicator"}},{"path":"action.description","expression":{"language":"text/cql","expression":"Inconsistent Illicit Drugs"}}],"action":[{"description":"Not for chronic pain management. Snooze 3 months"}]}]}]}
{"resourceType":"PlanDefinition","id":"opioidcds-11","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: opioidcds-11\u003c/p\u003e\u003cp\u003e\u003cb\u003eurl\u003c/b\u003e: \u003ca\u003ehttp://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-11\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: cdc-opioid-guidance (OFFICIAL)\u003c/p\u003e\u003cp\u003e\u003cb\u003eversion\u003c/b\u003e: 0.1.0\u003c/p\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e: cdc-opioid-11\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: CDC Opioid Prescribing Guideline Recommendation #11\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eECA Rule\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: draft\u003c/p\u003e\u003cp\u003e\u003cb\u003edate\u003c/b\u003e: 2018-03-19\u003c/p\u003e\u003cp\u003e\u003cb\u003epublisher\u003c/b\u003e: Centers for Disease Control and Prevention (CDC)\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient.\u003c/p\u003e\u003cp\u003e\u003cb\u003euseContext\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003ejurisdiction\u003c/b\u003e: \u003cspan\u003eUnited States of America\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epurpose\u003c/b\u003e: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eusage\u003c/b\u003e: Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.\u003c/p\u003e\u003cp\u003e\u003cb\u003ecopyright\u003c/b\u003e: © CDC 2016+.\u003c/p\u003e\u003cp\u003e\u003cb\u003etopic\u003c/b\u003e: \u003cspan\u003eOpioid Prescribing\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eauthor\u003c/b\u003e: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH: \u003c/p\u003e\u003cp\u003e\u003cb\u003erelatedArtifact\u003c/b\u003e: , \u003c/p\u003e\u003cp\u003e\u003cb\u003elibrary\u003c/b\u003e: \u003ca\u003ehttp://example.org/fhir/Library/opioidcds-recommendation-11\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eaction\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etitle\u003c/b\u003e: Existing patient has concurrent opioid and benzodiazepine prescriptions.\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Checking if the trigger prescription meets the inclusion criteria for recommendation #11 workflow.\u003c/p\u003e\u003cp\u003e\u003cb\u003edocumentation\u003c/b\u003e: \u003c/p\u003e\u003cp\u003e\u003cb\u003etrigger\u003c/b\u003e: \u003c/p\u003e\u003ch3\u003eConditions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eKind\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExpression\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eapplicability\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003egroupingBehavior\u003c/b\u003e: visual-group\u003c/p\u003e\u003cp\u003e\u003cb\u003eselectionBehavior\u003c/b\u003e: exactly-one\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.description\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.title\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003edynamicValue\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epath\u003c/b\u003e: action.extension\u003c/p\u003e\u003cp\u003e\u003cb\u003eexpression\u003c/b\u003e: \u003c/p\u003e\u003c/blockquote\u003e\u003ch3\u003eActions\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWill revise\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eRisk of overdose carefully considered and outweighed by benefit; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eN/A - see comment; snooze 3 mo\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"url":"http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-11","identifier":[{"use":"official","value":"cdc-opioid-guidance"}],"version":"0.1.0","name":"cdc-opioid-11","title":"CDC Opioid Prescribing Guideline Recommendation #11","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule","display":"ECA Rule"}]},"status":"draft","date":"2018-03-19","publisher":"Centers for Disease Control and Prevention (CDC)","description":"Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182888003","display":"Medication requested (situation)"}]}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"focus","display":"Clinical Focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"82423001","display":"Chronic pain (finding)"}]}}],"jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US","display":"United States of America"}]}],"purpose":"CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.","usage":"Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.","copyright":"© CDC 2016+.","topic":[{"text":"Opioid Prescribing"}],"author":[{"name":"Kensaku Kawamoto, MD, PhD, MHS"},{"name":"Bryn Rhodes"},{"name":"Floyd Eisenberg, MD, MPH"},{"name":"Robert McClure, MD, MPH"}],"relatedArtifact":[{"type":"documentation","display":"CDC guideline for prescribing opioids for chronic pain","url":"https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016#420"},{"type":"documentation","display":"MME Conversion Tables","url":"https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf"}],"library":["http://example.org/fhir/Library/opioidcds-recommendation-11"],"action":[{"title":"Existing patient has concurrent opioid and benzodiazepine prescriptions.","description":"Checking if the trigger prescription meets the inclusion criteria for recommendation #11 workflow.","documentation":[{"type":"documentation","document":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/recommendation-strength","code":"strong","display":"Strong"}]}},{"url":"http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence","valueCodeableConcept":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/evidence-quality","code":"low","display":"Low quality"}]}}]}}],"trigger":[{"type":"named-event","name":"medication-prescribe"}],"condition":[{"kind":"applicability","expression":{"description":"Check whether the existing patient is using opioids concurrently with benzodiazepines.","language":"text/cql","expression":"Inclusion Criteria"}}],"groupingBehavior":"visual-group","selectionBehavior":"exactly-one","dynamicValue":[{"path":"action.description","expression":{"language":"text/cql","expression":"Get Detail"}},{"path":"action.title","expression":{"language":"text/cql","expression":"Get Summary"}},{"path":"action.extension","expression":{"language":"text/cql","expression":"Get Indicator"}}],"action":[{"description":"Will revise"},{"description":"Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo"},{"description":"N/A - see comment; snooze 3 mo"}]}]}
{"resourceType":"PlanDefinition","id":"options-example","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e[Put rendering here]\u003c/div\u003e"},"contained":[{"resourceType":"ActivityDefinition","id":"activitydefinition-medicationrequest-1","status":"draft","kind":"MedicationRequest","productCodeableConcept":{"text":"Medication 1"}},{"resourceType":"ActivityDefinition","id":"activitydefinition-medicationrequest-2","status":"draft","kind":"MedicationRequest","productCodeableConcept":{"text":"Medication 2"}}],"title":"This example illustrates relationships between actions.","status":"draft","action":[{"groupingBehavior":"logical-group","selectionBehavior":"all","action":[{"id":"medication-action-1","title":"Administer Medication 1","definitionCanonical":"#activitydefinition-medicationrequest-1"},{"id":"medication-action-2","title":"Administer Medication 2","relatedAction":[{"actionId":"medication-action-1","relationship":"after-end","offsetDuration":{"value":1,"unit":"h"}}],"definitionCanonical":"#activitydefinition-medicationrequest-2"}]}]}
{"resourceType":"PlanDefinition","id":"zika-virus-intervention-initial","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/zika-virus-intervention-initial\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003ezika-virus-intervention\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExample Zika Virus Intervention\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eactive\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eZika Virus Management intervention describing the CDC Guidelines for Zika Virus Reporting and Management.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eZika Virus Management\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/zika-virus-intervention-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eZika Virus Assessment\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eIs Patient Pregnant\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Administer Zika Virus Exposure Assessment\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 100px;\"\u003e#administer-zika-virus-exposure-assessment\u003c/span\u003e\n                           \u003cbr/\u003e\n                           \u003cspan\u003e\n\t\t\t\t\t\t\t \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n\t\t\t\t\t\t\t\t\u003cb\u003edescription: \u003c/b\u003e\n\t\t\t\t\t\t\t\t\u003cspan\u003eAdminister Zika Virus Exposure Assessment\u003c/span\u003e\n\t\t\t\t\t\t\t\t\u003cbr/\u003e\n\t\t\t\t\t\t\t \u003c/span\u003e\n\t\t\t\t\t\t\t \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n\t\t\t\t\t\t\t\t\u003cb\u003ecategory: \u003c/b\u003e\n\t\t\t\t\t\t\t\t\u003cspan\u003eprocedure\u003c/span\u003e\n\t\t\t\t\t\t\t\t\u003cbr/\u003e\n\t\t\t\t\t\t\t \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Order Serum + Urine rRT-PCR Test\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 125px;\"\u003eActivityDefinition/order-serum-urine-rrt-pcr-test\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Order Serum Zika Virus IgM + Dengue Virus IgM\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 125px;\"\u003e#order-serum-zika-dengue-virus-igm\u003c/span\u003e\n                           \u003cbr/\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                                 \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                                    \u003cb\u003edescription: \u003c/b\u003e\n                                    \u003cspan\u003eOrder Serum Zika and Dengue Virus IgM\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                    \u003cb\u003erelated:\u003c/b\u003e\n                                    \u003cbr/\u003e\n                                    \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                       \u003cb\u003etype: \u003c/b\u003e\n                                       \u003cspan\u003edocumentation\u003c/span\u003e\n                                       \u003cbr/\u003e\n                                    \u003c/span\u003e\n                                    \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                       \u003cb\u003edisplay: \u003c/b\u003e\n                                       \u003cspan\u003eExplanation of diagnostic tests for Zika virus and which to use based on the patients clinical and exposure history.\u003c/span\u003e\n                                       \u003cbr/\u003e\n                                    \u003c/span\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                    \u003cb\u003ecategory: \u003c/b\u003e\n                                    \u003cspan\u003ediagnostic\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                           \u003cspan/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Consider IgM Antibody Testing\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 125px;\"\u003eActivityDefinition/consider-igm-antibody-testing\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Provide Mosquito Prevention and Contraception Advice\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cspan\u003e\n                           \u003cb\u003eStep: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003econdition: \u003c/b\u003e\n                              \u003cbr/\u003e\n                              \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                 \u003cb\u003ereference: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 125px;\"\u003e#provide-mosquito-prevention-advice\u003c/span\u003e\n                                 \u003cspan\u003e\n                                    \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                          \u003cb\u003edescription: \u003c/b\u003e\n                                          \u003cspan\u003eProvide mosquito prevention advice\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                          \u003cb\u003erelated:\u003c/b\u003e\n                                          \u003cbr/\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003etype: \u003c/b\u003e\n                                             \u003cspan\u003edocumentation\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003edisplay: \u003c/b\u003e\n                                             \u003cspan\u003eAdvice for patients about how to avoid Mosquito bites.\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                          \u003cb\u003erelated:\u003c/b\u003e\n                                          \u003cbr/\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003etype: \u003c/b\u003e\n                                             \u003cspan\u003edocumentation\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003edisplay: \u003c/b\u003e\n                                             \u003cspan\u003eAdvice for patients about which mosquito repellents are effective and safe to use in pregnancy. [DEET, IF3535 and Picardin are safe during]\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                          \u003cb\u003ecategory: \u003c/b\u003e\n                                          \u003cspan\u003ecommunication\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                    \u003c/span\u003e\n                                 \u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"/\u003e\n                        \u003c/span\u003e\n                        \u003cspan\u003e\n                           \u003cb\u003eStep: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003econdition: \u003c/b\u003e\n                              \u003cbr/\u003e\n                              \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                 \u003cb\u003ereference: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 125px;\"\u003eActivityDefinition/provide-contraception-advice\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"url":"http://example.org/PlanDefinition/zika-virus-intervention","identifier":[{"use":"official","value":"zika-virus-intervention"}],"version":"1.0.0","title":"Example Zika Virus Intervention","status":"active","date":"2016-11-14","description":"Zika Virus Management intervention describing the CDC Guidelines for Zika Virus Reporting and Management.","topic":[{"text":"Zika Virus Management"}],"relatedArtifact":[{"type":"derived-from","url":"https://www.cdc.gov/mmwr/volumes/65/wr/mm6539e1.htm?s_cid\u003dmm6539e1_w"},{"type":"successor","resource":"http://example.org/fhir/PlanDefinition/zika-virus-intervention"}],"library":["http://example.org/fhir/Library/zika-virus-intervention-logic"],"action":[{"title":"Zika Virus Assessment","trigger":[{"type":"named-event","name":"patient-view"}],"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Is Patient Pregnant"}}],"action":[{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Administer Zika Virus Exposure Assessment"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/administer-zika-virus-exposure-assessment"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Order Serum + Urine rRT-PCR Test"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/order-serum-urine-rrt-pcr-test"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Order Serum Zika Virus IgM + Dengue Virus IgM"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/order-serum-zika-dengue-virus-igm"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Consider IgM Antibody Testing"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/consider-igm-antibody-testing"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Provide Mosquito Prevention and Contraception Advice"}}],"action":[{"definitionCanonical":"http://example.org/fhir/ActivityDefinition/provide-mosquito-prevention-advice"},{"definitionCanonical":"http://example.org/fhir/ActivityDefinition/provide-contraception-advice"}]}]}]}
{"resourceType":"PlanDefinition","id":"protocol-example","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n\u003cp\u003e\n    \u003cb\u003eid: \u003c/b\u003eexample, \u003c/p\u003e\n\n  \u003cp\u003e\n    \u003cb\u003eidentifier: \u003c/b\u003e, \u003cb\u003esystem: \u003c/b\u003ehttp://acme.org, \u003cb\u003evalue: \u003c/b\u003eexample-1, \u003c/p\u003e\n  \u003cp\u003e\n    \u003cb\u003etitle: \u003c/b\u003eObesity Assessment Protocol, \u003c/p\u003e\n  \u003cp\u003e\n    \u003cb\u003estatus: \u003c/b\u003edraft, \u003c/p\u003e\n  \u003cp\u003e\n    \u003cb\u003etype: \u003c/b\u003econdition, \u003c/p\u003e\n  \u003cp\u003e\n    \u003cb\u003epurpose: \u003c/b\u003eExample of A medical algorithm for assessment and treatment of overweight and obesity, \u003c/p\u003e\n  \u003cp\u003e\n    \u003cb\u003eauthor: \u003c/b\u003e, \u003cb\u003edisplay: \u003c/b\u003eNational Heart, Lung, and Blood Institute http://www.nhlbi.nih.gov/health-pro/guidelines/current/obesity-guidelines/e_textbook/txgd/algorthm/algorthm.htm, \u003c/p\u003e\n  \u003cp\u003e\n    \u003cb\u003estep: \u003c/b\u003e, \u003cb\u003ename: \u003c/b\u003eMeasure BMI, \u003cb\u003edescription: \u003c/b\u003eMeasure, Weight, Height, Waist, Circumference; Calculate BMI  Weight must be measured so that the BMI can be calculated. Most charts are based on weights obtained with the patient wearing undergarments and no shoes. BMI can be manually calculated (kg/[height in meters]2), but is more easily obtained from a nomogram. Waist circumference is important because evidence suggests that abdominal fat is a particularly strong determinant of cardiovascular risk in those with a BMI of 25 to 34.9 kg/m2. Increased waist circumference can also be a marker of increased risk even in persons of normal weight. The technique for measuring waist circumference is described in the text. A nutrition assessment will also help to assess the diet and physical activity habits of overweight patients, \u003cb\u003eprecondition: \u003c/b\u003e, \u003cb\u003eunion: \u003c/b\u003e, \u003cb\u003edescription: \u003c/b\u003eThe practitioner must seek to determine whether the patient has ever been overweight. While a technical definition is provided, a simple question such as \u0027Have you ever been overweight?\u0027 will accomplish the same goal. Questions directed towards weight history, dietary habits, physical activities, and medications may provide useful information about the origins of obesity in particular patients., \u003cb\u003econdition: \u003c/b\u003e, \u003cb\u003etype: \u003c/b\u003e, \u003cb\u003ecoding: \u003c/b\u003e, \u003cb\u003esystem: \u003c/b\u003ehttp://acme.org, \u003cb\u003ecode: \u003c/b\u003e1234, \u003cb\u003edisplay: \u003c/b\u003eObesity, \u003cb\u003evalueBoolean: \u003c/b\u003etrue, \u003cb\u003eunion: \u003c/b\u003e, \u003cb\u003edescription: \u003c/b\u003eBMI Measured in Past 2 Years  For those who have not been overweight, a 2 year interval is appropriate for the reassessment of BMI. While this time span is not evidence-based, it is believed to be a reasonable compromise between the need to identify weight gain at an early stage and the need to limit the time, effort, and cost of repeated measurements., \u003cb\u003econdition: \u003c/b\u003e, \u003cb\u003etype: \u003c/b\u003e, \u003cb\u003etext: \u003c/b\u003eBMI in last 2 years, \u003cb\u003evalueBoolean: \u003c/b\u003efalse, \u003cb\u003eactivity: \u003c/b\u003e, \u003cb\u003edetail: \u003c/b\u003e, \u003cb\u003ecategory: \u003c/b\u003eprocedure, \u003cb\u003ecode: \u003c/b\u003e, \u003cb\u003ecoding: \u003c/b\u003e, \u003cb\u003esystem: \u003c/b\u003ehttp://loinc.org, \u003cb\u003ecode: \u003c/b\u003e39156-5, \u003cb\u003edisplay: \u003c/b\u003eBody mass index (BMI) [Ratio], \u003cb\u003eperformer: \u003c/b\u003e, \u003cb\u003edisplay: \u003c/b\u003eNurse Ratched, \u003cb\u003edescription: \u003c/b\u003eExtra information on activity , \u003c/p\u003e\n    \u003c/div\u003e"},"contained":[{"resourceType":"ActivityDefinition","id":"procedure","status":"draft","description":"Extra information on activity ","kind":"ServiceRequest","code":{"coding":[{"system":"http://loinc.org","code":"39156-5","display":"Body mass index (BMI) [Ratio]"}]},"participant":[{"type":"practitioner","role":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/practitioner-role","code":"doctor","display":"Doctor"}]}}]}],"identifier":[{"system":"http://acme.org","value":"example-1"}],"title":"Obesity Assessment Protocol","type":{"coding":[{"code":"clinical-protocol"}]},"status":"draft","useContext":[{"code":{"code":"focus"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"414916001","display":"Obesity (disorder)"}]}}],"purpose":"Example of A medical algorithm for assessment and treatment of overweight and obesity","author":[{"name":"National Heart, Lung, and Blood Institute","telecom":[{"system":"url","value":"https://www.nhlbi.nih.gov/health-pro/guidelines"}]}],"relatedArtifact":[{"type":"derived-from","display":"Overweight and Obesity Treatment Guidelines","url":"http://www.nhlbi.nih.gov/health-pro/guidelines/current/obesity-guidelines/e_textbook/txgd/algorthm/algorthm.htm"}],"goal":[{"id":"reduce-bmi-ratio","category":{"text":"Treatment"},"description":{"text":"Reduce BMI to below 25"},"priority":{"text":"medium-priority"},"start":{"text":"When the patient\u0027s BMI Ratio is at or above 25"},"addresses":[{"coding":[{"system":"http://snomed.info/sct","code":"414916001","display":"Obesity (disorder)"}]}],"documentation":[{"type":"justification","display":"Evaluation and Treatment Strategy","url":"https://www.nhlbi.nih.gov/health-pro/guidelines/current/obesity-guidelines/e_textbook/txgd/42.htm"}],"target":[{"measure":{"coding":[{"system":"http://loinc.org","code":"39156-5","display":"Body mass index (BMI) [Ratio]"}]},"detailRange":{"high":{"value":24.9,"unit":"kg/m2"}},"due":{"value":1,"unit":"a"}}]}],"action":[{"title":"Measure BMI","description":"Measure, Weight, Height, Waist, Circumference; Calculate BMI","textEquivalent":"Weight must be measured so that the BMI can be calculated. Most charts are based on weights obtained with the patient wearing undergarments and no shoes. BMI can be manually calculated (kg/[height in meters]2), but is more easily obtained from a nomogram. Waist circumference is important because evidence suggests that abdominal fat is a particularly strong determinant of cardiovascular risk in those with a BMI of 25 to 34.9 kg/m2. Increased waist circumference can also be a marker of increased risk even in persons of normal weight. The technique for measuring waist circumference is described in the text. A nutrition assessment will also help to assess the diet and physical activity habits of overweight patients","goalId":["reduce-bmi-ratio"],"condition":[{"kind":"applicability","expression":{"description":"The practitioner must seek to determine whether the patient has ever been overweight. While a technical definition is provided, a simple question such as \u0027Have you ever been overweight?\u0027 will accomplish the same goal. Questions directed towards weight history, dietary habits, physical activities, and medications may provide useful information about the origins of obesity in particular patients.  For those who have not been overweight, a 2 year interval is appropriate for the reassessment of BMI. While this time span is not evidence-based, it is believed to be a reasonable compromise between the need to identify weight gain at an early stage and the need to limit the time, effort, and cost of repeated measurements.","language":"text/cql","expression":"exists ([Condition: Obesity]) or not exists ([Observation: BMI] O where O.effectiveDateTime 2 years or less before Today())"}}],"requiredBehavior":"must-unless-documented","cardinalityBehavior":"single","definitionCanonical":"#procedure"}]}
{"resourceType":"PlanDefinition","id":"zika-virus-intervention","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eId: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003ePlanDefinition/zika-virus-intervention\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eIdentifier: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003evalue: \u003c/b\u003e\n                  \u003cspan\u003ezika-virus-intervention\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTitle: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eExample Zika Virus Intervention\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eStatus: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eactive\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eDescription: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003eZika Virus Management intervention describing the CDC Guidelines for Zika Virus Reporting and Management.\u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eTopic: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003etext: \u003c/b\u003e\n                     \u003cspan\u003eZika Virus Management\u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ctable class\u003d\"grid dict\"\u003e\n            \u003ctr\u003e\n               \u003ctd\u003e\n                  \u003cb\u003eLibrary: \u003c/b\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n            \u003ctr\u003e\n               \u003ctd style\u003d\"padding-left: 25px; padding-right: 25px;\"\u003e\n                  \u003cb\u003ereference: \u003c/b\u003e\n                  \u003cspan\u003eLibrary/zika-virus-intervention-logic\u003c/span\u003e\n               \u003c/td\u003e\n            \u003c/tr\u003e\n         \u003c/table\u003e\n         \u003cp/\u003e\n         \u003ch2\u003eActions\u003c/h2\u003e\n         \u003cp style\u003d\"width: 100%;\" class\u003d\"hierarchy\"\u003e\n            \u003cspan\u003e\n               \u003cb\u003eStep: \u003c/b\u003e\n               \u003cbr/\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003etitle: \u003c/b\u003e\n                  \u003cspan\u003eZika Virus Assessment\u003c/span\u003e\n                  \u003cbr/\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cb\u003econdition: \u003c/b\u003e\n                  \u003cbr/\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003etype: \u003c/b\u003e\n                     \u003cspan\u003eapplicability\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n                  \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                     \u003cb\u003eexpression: \u003c/b\u003e\n                     \u003cspan\u003eIs Patient Pregnant\u003c/span\u003e\n                     \u003cbr/\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n               \u003cspan style\u003d\"padding-left: 25px;\"\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Administer Zika Virus Exposure Assessment\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 100px;\"\u003e#administer-zika-virus-exposure-assessment\u003c/span\u003e\n                           \u003cbr/\u003e\n                           \u003cspan\u003e\n\t\t\t\t\t\t\t \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n\t\t\t\t\t\t\t\t\u003cb\u003edescription: \u003c/b\u003e\n\t\t\t\t\t\t\t\t\u003cspan\u003eAdminister Zika Virus Exposure Assessment\u003c/span\u003e\n\t\t\t\t\t\t\t\t\u003cbr/\u003e\n\t\t\t\t\t\t\t \u003c/span\u003e\n\t\t\t\t\t\t\t \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n\t\t\t\t\t\t\t\t\u003cb\u003ecategory: \u003c/b\u003e\n\t\t\t\t\t\t\t\t\u003cspan\u003eprocedure\u003c/span\u003e\n\t\t\t\t\t\t\t\t\u003cbr/\u003e\n\t\t\t\t\t\t\t \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Order Serum + Urine rRT-PCR Test\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 125px;\"\u003eActivityDefinition/order-serum-urine-rrt-pcr-test\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Order Serum Zika Virus IgM + Dengue Virus IgM\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 125px;\"\u003e#order-serum-zika-dengue-virus-igm\u003c/span\u003e\n                           \u003cbr/\u003e\n                           \u003cspan\u003e\n                              \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                                 \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                                    \u003cb\u003edescription: \u003c/b\u003e\n                                    \u003cspan\u003eOrder Serum Zika and Dengue Virus IgM\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                    \u003cb\u003erelated:\u003c/b\u003e\n                                    \u003cbr/\u003e\n                                    \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                       \u003cb\u003etype: \u003c/b\u003e\n                                       \u003cspan\u003edocumentation\u003c/span\u003e\n                                       \u003cbr/\u003e\n                                    \u003c/span\u003e\n                                    \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                       \u003cb\u003edisplay: \u003c/b\u003e\n                                       \u003cspan\u003eExplanation of diagnostic tests for Zika virus and which to use based on the patients clinical and exposure history.\u003c/span\u003e\n                                       \u003cbr/\u003e\n                                    \u003c/span\u003e\n                                 \u003c/span\u003e\n                                 \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                    \u003cb\u003ecategory: \u003c/b\u003e\n                                    \u003cspan\u003ediagnostic\u003c/span\u003e\n                                    \u003cbr/\u003e\n                                 \u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                           \u003cspan/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Consider IgM Antibody Testing\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003ereference: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 125px;\"\u003eActivityDefinition/consider-igm-antibody-testing\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"/\u003e\n                  \u003c/span\u003e\n                  \u003cspan\u003e\n                     \u003cb\u003eStep: \u003c/b\u003e\n                     \u003cbr/\u003e\n                     \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                        \u003cb\u003econdition: \u003c/b\u003e\n                        \u003cbr/\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003etype: \u003c/b\u003e\n                           \u003cspan\u003eapplicability\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                        \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                           \u003cb\u003eexpression: \u003c/b\u003e\n                           \u003cspan\u003eShould Provide Mosquito Prevention and Contraception Advice\u003c/span\u003e\n                           \u003cbr/\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                     \u003cspan style\u003d\"padding-left: 50px;\"\u003e\n                        \u003cspan\u003e\n                           \u003cb\u003eStep: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003econdition: \u003c/b\u003e\n                              \u003cbr/\u003e\n                              \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                 \u003cb\u003ereference: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 125px;\"\u003e#provide-mosquito-prevention-advice\u003c/span\u003e\n                                 \u003cspan\u003e\n                                    \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                       \u003cbr/\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                          \u003cb\u003edescription: \u003c/b\u003e\n                                          \u003cspan\u003eProvide mosquito prevention advice\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                          \u003cb\u003erelated:\u003c/b\u003e\n                                          \u003cbr/\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003etype: \u003c/b\u003e\n                                             \u003cspan\u003edocumentation\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003edisplay: \u003c/b\u003e\n                                             \u003cspan\u003eAdvice for patients about how to avoid Mosquito bites.\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                                          \u003cb\u003erelated:\u003c/b\u003e\n                                          \u003cbr/\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003etype: \u003c/b\u003e\n                                             \u003cspan\u003edocumentation\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                          \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                             \u003cb\u003edisplay: \u003c/b\u003e\n                                             \u003cspan\u003eAdvice for patients about which mosquito repellents are effective and safe to use in pregnancy. [DEET, IF3535 and Picardin are safe during]\u003c/span\u003e\n                                             \u003cbr/\u003e\n                                          \u003c/span\u003e\n                                       \u003c/span\u003e\n                                       \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                          \u003cb\u003ecategory: \u003c/b\u003e\n                                          \u003cspan\u003ecommunication\u003c/span\u003e\n                                          \u003cbr/\u003e\n                                       \u003c/span\u003e\n                                    \u003c/span\u003e\n                                 \u003c/span\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"/\u003e\n                        \u003c/span\u003e\n                        \u003cspan\u003e\n                           \u003cb\u003eStep: \u003c/b\u003e\n                           \u003cbr/\u003e\n                           \u003cspan style\u003d\"padding-left: 75px;\"\u003e\n                              \u003cb\u003econdition: \u003c/b\u003e\n                              \u003cbr/\u003e\n                              \u003cspan style\u003d\"padding-left: 100px;\"\u003e\n                                 \u003cb\u003ereference: \u003c/b\u003e\n                                 \u003cbr/\u003e\n                                 \u003cspan style\u003d\"padding-left: 125px;\"\u003eActivityDefinition/provide-contraception-advice\u003c/span\u003e\n                                 \u003cbr/\u003e\n                              \u003c/span\u003e\n                           \u003c/span\u003e\n                        \u003c/span\u003e\n                     \u003c/span\u003e\n                  \u003c/span\u003e\n               \u003c/span\u003e\n            \u003c/span\u003e\n         \u003c/p\u003e\n      \u003c/div\u003e"},"url":"http://example.org/PlanDefinition/zika-virus-intervention","identifier":[{"use":"official","value":"zika-virus-intervention"}],"version":"2.0.0","title":"Example Zika Virus Intervention","status":"active","date":"2017-01-12","description":"Zika Virus Management intervention describing the CDC Guidelines for Zika Virus Reporting and Management.","useContext":[{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"age"},"valueRange":{"low":{"value":12,"unit":"a"}}},{"code":{"system":"http://terminology.hl7.org/CodeSystem/usage-context-type","code":"user"},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"309343006","display":"Physician"}]}}],"topic":[{"text":"Zika Virus Management"}],"relatedArtifact":[{"type":"derived-from","url":"https://www.cdc.gov/mmwr/volumes/65/wr/mm6539e1.htm?s_cid\u003dmm6539e1_w"},{"type":"predecessor","resource":"http://example.org/fhir/PlanDefinition/zika-virus-intervention-initial"}],"library":["http://example.org/fhir/Library/zika-virus-intervention-logic"],"action":[{"title":"Zika Virus Assessment","trigger":[{"type":"named-event","name":"patient-view"}],"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Is Patient Pregnant"}}],"action":[{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Administer Zika Virus Exposure Assessment"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/administer-zika-virus-exposure-assessment"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Order Serum + Urine rRT-PCR Test"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/order-serum-urine-rrt-pcr-test"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Order Serum Zika Virus IgM + Dengue Virus IgM"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/order-serum-zika-dengue-virus-igm"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Consider IgM Antibody Testing"}}],"definitionCanonical":"http://example.org/fhir/ActivityDefinition/consider-igm-antibody-testing"},{"condition":[{"kind":"applicability","expression":{"language":"text/cql","expression":"Should Provide Mosquito Prevention and Contraception Advice"}}],"action":[{"definitionCanonical":"http://example.org/fhir/ActivityDefinition/provide-mosquito-prevention-advice"},{"definitionCanonical":"http://example.org/fhir/ActivityDefinition/provide-contraception-advice"}]}]}]}